<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">FLUTAMIDE <img border="0" src="../images/pr.gif"/></span><br/>(flu'ta-mide)<br/><span class="topboxtradename">Eulexin<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">antiandrogen</span><br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>125 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Nonsteroidal, nonhormonal, antiandrogenic that inhibits androgen uptake or binding of androgen to target tissues (i.e., prostatic
         cancer cells).
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Interferes with the binding of both testosterone and dihydrotestosterone to target tissue (i.e., prostate cancer cells).</p>
<h1><a name="uses">Uses</a></h1>
<p>In combination with luteinizing hormone-releasing hormone agonists (i.e., leuprolide) or castration for early stage and metastatic
         prostate cancer.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to flutamide; severe liver impairment if ALT is equal to twice the normal value; pregnancy (category D),
         lactation.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prostate Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg (2 caps) q8h<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Use with caution in patients with severe hepatic impairment.</li>
<li>Store at 2°30° C (36°86° F) in a tightly closed, light-resistant container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Drowsiness, confusion, depression, anxiety, nervousness. <span class="typehead">GI:</span> Diarrhea, nausea, vomiting, anorexia, hepatitis, cholestatic jaundice, encephalopathy, hepatic necrosis, <span class="speceff-life">acute hepatic failure</span>, may increase ALT, AST, bilirubin. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Hot flashes, loss of libido, impotence</span>. <span class="typehead">Hematologic:</span> Anemia, leukopenia, thrombocytopenia. <span class="typehead">Skin:</span> Rash. <span class="typehead">Body as a Whole:</span> Edema. <span class="typehead">Endocrine:</span> Gynecomastia, galactorrhea. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> may increase INR in patients on <b>warfarin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> Antiandrogenic activity 2.2 h; symptomatic relief 24 wk. <span class="typehead">Duration:</span> 3 mo2.5 y, with an average of 10.5 mo. <span class="typehead">Metabolism:</span> Metabolized in liver to at least 10 different metabolites; the major metabolite, 2-hydroxyflutamide (SCH-16423), is an alpha-hydroxylated
      derivative that is biologically active. <span class="typehead">Elimination:</span> 98% excreted in urine. <span class="typehead">Half-Life:</span> 56 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor therapeutic response with acid and alkaline phosphatase tests, bone and liver scans, chest x-ray, and physical exam.</li>
<li>Monitor for symptomatic relief of bone pain.</li>
<li>Assess for development of gynecomastia and galactorrhea; if these become bothersome, dosage reduction may be warranted.</li>
<li>Lab tests: Monitor liver function and serum bilirubin periodically.</li>
<li>Monitor for and report development of a lupus-like syndrome.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of potential adverse effects of therapy.</li>
<li>Notify physician immediately of the following: Pain in upper abdomen, yellowing of skin and eyes, dark urine, respiratory
            problems, rashes on face, difficulty urinating, sore throat, fever, chills.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>